FOR IMMEDIATE RELEASE…Vancouver, British Columbia: RavenQuest BioMed Inc. (the “Company” or “RavenQuest”) – (CSE: RQB) announces that further to the Company’s news release dated September 29, 2017 announcing the acquisition (the “AGB Acquisition”) of 99.23% of the outstanding common shares of Alberta Green Biotech Inc. (“AGB”), and the Company’s news release dated October 23, 2017, the Company is pleased to announce it has completed the acquisition of the remaining 64,000 common shares of Alberta Green Biotech Inc. (“AGB”) in exchange for the issuance of 9,152 common shares of the Company on the basis of 0.143015519 common shares of the Company for every one (1) common share of AGB. Following completion of this acquisition, the Company now owns 100% of the issued and outstanding common shares of AGB.
The AGB Acquisition, together with the acquisition of the business and assets of the CL2G group of companies (the “CL2G Group”) announced September 28, 2017, are further described in the Company’s Canadian Securities Exchange (the “Exchange”) Form 2A Listing Statement dated September 28, 2017 (the “Listing Statement”) filed under the Company’s profile on the Exchange’s website.
About RavenQuest BioMed Inc.
RavenQuest BioMed Inc. is a diversified publicly traded cannabis company with divisions focused upon cannabis production, management services & consulting and specialized research & development.
On Behalf of the Board of Directors of
RAVENQUEST BIOMED INC.
Chief Executive Officer
For further information, please contact:
Neither Canadian Stock Exchange nor its Regulation Services Provider (as that term is defined in the policies of the Canadian Stock Exchange) accepts responsibility for the adequacy or accuracy of this press release, which has been prepared by management.